This study is a single site, prospective, single arm evaluation of the safety and effectiveness of the Healionics STARgraft (10401) hemodialysis access graft. The study is enrolling patients with End Stage Renal Disease (ESRD) requiring hemodialysis via a prosthetic vascular graft. The study proposes to evaluate the performance of the investigational STARgraft (10401) compared to the ePTFE controls in a prior study (NCT03916731) and to published results, over a period of 6 months. Additional data out to 36 months post-implantation may be captured.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
20
Participants will be implanted with 6mm diameter STARgraft (10401) grafts as an upper arm Brachial Artery to Axillary Vein shunt for hemodialysis access.
Italian Hospital
Asunción, Paraguay
RECRUITINGEffectiveness - Primary unassisted patency
Primary unassisted patency, defined as the percentage of grafts retaining adequate flow for dialysis without requiring any surgical or endovascular procedure to maintain or re-establish its function.
Time frame: 6 months
Safety - Serious Device Related Adverse Events
Incidence of serious device-related adverse events.
Time frame: 6 months
Primary unassisted patency
Primary unassisted patency, defined as the percentage of grafts retaining adequate flow for dialysis without requiring any surgical or endovascular procedure to maintain or re-establish its function.
Time frame: 12, 18, 24 and 36 months
Assisted primary patency
Measured as the percentage of patients retaining assisted primary patency at the timepoints. Assisted primary patency begins when an access requires surgical or endovascular interventions designed to maintain the functionality of a patent access and ends at the first occlusion (thrombosis).
Time frame: 6, 12, 18, 24 and 36 months
Incidence of graft infections
Time frame: 6, 12, 18, 24 and 36 months
Incidence of serious device-related adverse events
Time frame: 12, 18, 24 and 36 months
Incidence of major events
Defined as adverse events requiring surgical or percutaneous intervention, or adverse events impacting or delaying graft use resulting from graft implant or use of the graft for hemodialysis
Time frame: 6, 12, 18, 24 and 36 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.